Cytek Biosciences, Inc. has introduced the Expanded Small Particle Detection (ESP™) option for its Cytek Aurora™ CS system. This is the first commercially available small particle detector on a cell sorter, representing a significant advancement for fast-growing research fields, including drug development, cell therapy, disease diagnostics, circulating tumor cells, regenerative medicine, and vaccine development.
Exosomes and extracellular vesicles (EVs), once considered cellular waste, are now recognized as key players in intercellular communication, disease progression, and therapeutic assistance. With the surge in research interest fueled by technological innovations, EVs have become the central focus of an increasing number of scientific publications and clinical trials. Thanks to Cytek's ESP detection option, particles as small as 70 nm can now be studied and sorted for further analysis, providing researchers with the ability to characterize the full spectrum of small particle emissions.
"As the first company to offer ESP detection on a cell sorter, we are setting a new standard for small particle research," said Ming Yan, Ph.D., Technical Director at Cytek Biosciences.
Cytek Aurora™ CS system is based on Spectrum Profiling™ (FSP™) technology, known for its ability to recognize and sort even the most complex cell populations with unparalleled sensitivity. The system allows seamless transition from analyzer to sorter without the need to rework panels or change detector configurations, enabling researchers to isolate and study identical cell populations. It also supports applications such as single-cell RNA sequencing, proteomics, and cell biology, making it a versatile tool for researchers who require flexibility and precision. Additionally, analyses developed on conventional flow cytometers can easily be performed on the Cytek Aurora™ CS system, minimizing downtime and maximizing throughput.
"With the ESP detection option, Cytek continues its commitment to innovation, helping researchers address the most pressing challenges in biomedical sciences," added Yan. "We are at the forefront of exosome and extracellular vesicle research and plan to continue developing advanced tools and technologies that solve the unique challenges of studying these nanoscale particles."
Original article: Cytek Biosciences, Inc.
For more detailed information, please visit the product page or contact our managers, who will be happy to provide all the necessary information.